InflaRx (IFRX)

• Market cap: $83.3M
• 1 day: -2.38%
• 5 days: -24.07%
• 1 month: 42.54%
• 3 months: 57.69%
• 6 months: 0.82%
• Year to date: -50.8%
• 1 year: -15.17%
• 5 years: -74.38%
• 10 years: -91.79%
• Sector: Healthcare
• Industry: Biotechnology

About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 74

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1.05% less ownership

Funds ownership: 26.1% [Q1] → 25.05% (-1.05%) [Q2]

10% less funds holding

Funds holding: 31 [Q1] → 28 (-3) [Q2]

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

26% less capital invested

Capital invested by funds: $17.9M [Q1] → $13.3M (-$4.57M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6
• Avg. target: $6
• High target: $6

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Keller

$6

Buy Assumed

2 Sep 2025